Repligen (NASDAQ:RGEN) Sees Large Volume Increase – Should You Buy?

Shares of Repligen Corporation (NASDAQ:RGEN) saw unusually-strong trading volume on Friday. 1,089,652 shares were traded during mid-day trading, an increase of 3% from the average daily volume of 1,053,129 shares. The stock last traded at $173.3620 and had previously closed at $188.64.

Analysts Set New Price Targets

A number of research analysts have weighed in on RGEN shares. Royal Bank Of Canada increased their target price on Repligen from $185.00 to $200.00 and gave the company an “outperform” rating in a report on Wednesday. Wells Fargo & Company boosted their price objective on Repligen from $180.00 to $185.00 and gave the company an “overweight” rating in a research report on Thursday, July 30th. Zacks Research lowered shares of Repligen from a “strong-buy” rating to a “hold” rating in a research report on Monday, September 28th. Canaccord Genuity Group raised their price objective on Repligen from $145.00 to $180.00 and gave the stock a “hold” rating in a research report on Monday, October 19th. Finally, Benchmark raised Repligen from a “hold” rating to a “buy” rating and set a $185.00 target price on the stock in a report on Tuesday, July 7th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $178.57.

Repligen Trading Down 7.6%

The firm has a market cap of $9.84 billion, a PE ratio of -832.18, a PEG ratio of 3.35 and a beta of 1.08. The company has a debt-to-equity ratio of 0.27, a current ratio of 9.88 and a quick ratio of 7.64. The business has a 50-day moving average price of $178.12 and a two-hundred day moving average price of $145.19.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Tuesday, October 27th. The biotechnology company reported $0.53 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.46 by $0.07. Repligen had a negative net margin of 1.47% and a positive return on equity of 5.49%. The firm had revenue of $209.31 million for the quarter, compared to the consensus estimate of $206.70 million. During the same quarter in the previous year, the firm posted $0.46 EPS. The firm’s quarterly revenue was up 10.9% on a year-over-year basis. Analysts forecast that Repligen Corporation will post 2.07 EPS for the current year.

Hedge Funds Weigh In On Repligen

Institutional investors have recently added to or reduced their stakes in the company. North Dakota State Investment Board raised its position in shares of Repligen by 4.1% during the 3rd quarter. North Dakota State Investment Board now owns 1,630 shares of the biotechnology company’s stock valued at $313,000 after acquiring an additional 64 shares during the last quarter. Farther Finance Advisors LLC lifted its holdings in shares of Repligen by 35.5% in the third quarter. Farther Finance Advisors LLC now owns 374 shares of the biotechnology company’s stock valued at $72,000 after purchasing an additional 98 shares in the last quarter. ABS Investment Management LLC acquired a new stake in Repligen in the 2nd quarter valued at approximately $191,016,000. State of Alaska Department of Revenue grew its position in Repligen by 2.9% in the third quarter. State of Alaska Department of Revenue now owns 5,346 shares of the biotechnology company’s stock valued at $1,027,000 after purchasing an additional 150 shares in the last quarter. Finally, Crossmark Global Holdings Inc. lifted its position in shares of Repligen by 3.5% in the third quarter. Crossmark Global Holdings Inc. now owns 4,525 shares of the biotechnology company’s stock valued at $870,000 after buying an additional 152 shares during the last quarter. 97.64% of the stock is owned by institutional investors.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) develops and manufactures bioprocessing technologies used in the production of biological medicines. Its products support key stages of biopharmaceutical manufacturing, including upstream processing, downstream purification, filtration, process monitoring and fluid management.

The company’s offerings include chromatography products, filtration systems, single-use technologies, process analytics equipment and critical biological materials such as recombinant proteins.